drugset
drugset / Trial / NCT06692491

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

NCT06692491 ↗

Phase 2 Not yet recruiting 200 enrolled Peking University Shenzhen Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

Timeline

Start
2025-01-01
Primary completion
2027-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 20 mg/kg —
Subject Alectinib Small molecule 600 mg —
Subject Atezolizumab Monoclonal antibody 1200 mg —
Subject Camrelizumab Monoclonal antibody 200 mg —
Subject Cisplatin Other / unclassified 90 mg/m2 —
Subject Durvalumab Monoclonal antibody 10 mg/kg —
Subject Entrectinib Small molecule 600 mg —
Subject Envafolimab Monoclonal antibody 150 mg —
Subject Epirubicin Small molecule 90 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Imatinib Small molecule 400 mg —
Subject Irinotecan Small molecule 125 mg/m2 —
Subject Nivolumab Monoclonal antibody 3 mg/kg —
Subject Osimertinib Small molecule 80 mg —
Subject Paclitaxel Small molecule 260 mg/m2 —
Subject Palbociclib Small molecule 125 mg —
Subject Pamiparib Small molecule 60 mg —
Subject Pembrolizumab Monoclonal antibody 200 mg —
Subject Pyrotinib Small molecule 400 mg —
Subject Savolitinib Small molecule 300 mg —
Subject Serplulimab Monoclonal antibody 3 mg/kg —
Subject Sintilimab Monoclonal antibody 200 mg —
Subject Tislelizumab Monoclonal antibody 200 mg —
Subject Toripalimab Monoclonal antibody 240 unknown —
Subject Vemurafenib Small molecule 960 mg —
Subject Vinorelbine Small molecule 25 mg/m2 —
Subject Vinorelbine Small molecule 30 mg/m2 —
Subject fluorouracil Small molecule 600 mg/m2 —

Indications

No indication recorded.